NasdaqCM:TCON

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has TRACON Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TCON is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: TCON's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-9.1%

TCON

0.7%

US Biotechs

1.4%

US Market


1 Year Return

131.5%

TCON

40.9%

US Biotechs

22.6%

US Market

Return vs Industry: TCON exceeded the US Biotechs industry which returned 41.5% over the past year.

Return vs Market: TCON exceeded the US Market which returned 22.8% over the past year.


Shareholder returns

TCONIndustryMarket
7 Day-9.1%0.7%1.4%
30 Day13.3%5.2%4.9%
90 Day105.3%23.7%14.6%
1 Year131.5%131.5%43.2%40.9%25.4%22.6%
3 Year-65.3%-65.3%27.1%20.5%46.8%37.0%
5 Year-86.7%-86.7%58.4%46.0%132.0%106.1%

Long-Term Price Volatility Vs. Market

How volatile is TRACON Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TRACON Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

8.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TCON is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TCON is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TCON's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TCON is overvalued based on its PB Ratio (9x) compared to the US Biotechs industry average (4.5x).


Next Steps

Future Growth

How is TRACON Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

38.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TCON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TCON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TCON is forecast to have no revenue next year.

High Growth Revenue: TCON is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TCON's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TRACON Pharmaceuticals performed over the past 5 years?

2.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TCON is currently unprofitable.

Growing Profit Margin: TCON is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TCON is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare TCON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TCON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: TCON has a negative Return on Equity (-105.9%), as it is currently unprofitable.


Next Steps

Financial Health

How is TRACON Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: TCON's short term assets ($27.5M) exceed its short term liabilities ($10.0M).

Long Term Liabilities: TCON's short term assets ($27.5M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: TCON's debt to equity ratio (23.9%) is considered satisfactory.

Reducing Debt: TCON's debt to equity ratio has increased from 17.1% to 23.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TCON has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TCON has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.8% each year


Next Steps

Dividend

What is TRACON Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TCON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TCON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TCON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TCON's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TCON's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Charles Theuer (56 yo)

14.58yrs

Tenure

US$1,085,324

Compensation

Dr. Charles P. Theuer, M.D., Ph.D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since June 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June 2...


CEO Compensation Analysis

Compensation vs Market: Charles's total compensation ($USD1.09M) is above average for companies of similar size in the US market ($USD533.25K).

Compensation vs Earnings: Charles's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Charles Theuer
CEO, President & Director14.58yrsUS$1.09m1.39%
$ 1.9m
Scott Brown
Chief Accounting Officer & Head of Finance2yrsUS$501.25k0.010%
$ 14.5k
Mark Wiggins
Chief Business Officer2.67yrsUS$603.02k0.10%
$ 138.9k
Bonne Adams
Executive Vice President of Clinical Operations6.5yrsno datano data
Shahe Garabedian
Senior VP & Head of Quality Assurance1yrno datano data
James Freddo
Chief Medical Officer0.67yrno datano data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: TCON's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Charles Theuer
CEO, President & Director14.58yrsUS$1.09m1.39%
$ 1.9m
Stephen Worland
Independent Director5.92yrsUS$73.63k0.0055%
$ 7.6k
William LaRue
Independent Director6.5yrsUS$61.75k0.0098%
$ 13.6k
Martin Mattingly
Independent Director6.08yrsUS$55.50k0.0055%
$ 7.6k
Saundra Pelletier
Independent Director0.83yrno data0.040%
$ 55.8k
James Twiford
Independent Director12.33yrsUS$46.75k0.0055%
$ 7.6k
Stanton Gerson
Member of the Scientific Advisory Boardno datano datano data
Jeffrey Hager
Member of the Scientific Advisory Board4.08yrsno datano data

6.1yrs

Average Tenure

62yo

Average Age

Experienced Board: TCON's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TCON insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 233.8%.


Top Shareholders

Company Information

TRACON Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TRACON Pharmaceuticals, Inc.
  • Ticker: TCON
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$138.763m
  • Shares outstanding: 13.68m
  • Website: https://www.traconpharma.com

Number of Employees


Location

  • TRACON Pharmaceuticals, Inc.
  • 4350 La Jolla Village Drive
  • Suite 800
  • San Diego
  • California
  • 92122
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TCONNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2015
T051DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2015

Biography

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lea...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 23:41
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.